Lisuride

Lisuride is a dopamine receptor agonist. Lisuride is semisynthetic ergot derivative belonging to the 8a-aminoergoline group. Lisuride is effective in the treatment of Parkinson's disease especially in the latter stages of disease when the treatment fails. It is reported to have serotonergic activity and has been used in disorders associated with hyperprolactinemia. Lisuride is not available in any combination preparations. Lisuride is administered orally.

Lisuride is primarily indicated in conditions like Cushing's syndrome, Hyperprolactinemia, Migraine prophylaxis, Neuroleptic malignant syndrome, Parkinsonism, Parkinson's disease, and can also be given in adjunctive therapy as an alternative drug of choice in Acromegaly, Galactorrhea.

Lisuride is contraindicated in conditions like Peripheral vascular disease, Pituitary disease, Coronary heart disease.

The severe or irreversible adverse effects of Lisuride, which give rise to further complications include Confusion, Drowsiness, Delirium, Memory disturbance, Visual hallucination, Frequent & vivid dreams, Vivid dreams. The signs and symptoms that are produced after the acute overdosage of Lisuride include Hallucinations, Exanthema, Satyriasis. The symptomatic adverse reactions produced by Lisuride are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Nausea, Vomiting, Abdominal pain, Itching, Weight gain.

Liver disease may alter the response to drugs in several ways. Prescribing should be kept to a minimum in all patients with severe liver disease, especially if jaundice, ascites, or evidence of encephalopathy present. Consider dose reduction in renal failure to avoid possibility of toxicity, increased sensitivity, and side effects.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

0.002 mg/ kg (0.002 (0.002)) As recommended. IV — As Required 0.035 mg/ kg (0.035 (0.035)) 24 hourly SC — 0.2 to 4.5 mg (2.4 (2.35)) 24 hourly PO — Initially 0.2mg, increased by 0.2mg weekly until a clinical effect.

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Lisuride was found.

Tab